• LLY is just 6.5% away from its all-time high, which made it the first healthcare company in the world to reach a $1 trillion market cap.
• Late Monday, Lilly released encouraging Phase 1b trial data for Verve-102, an experimental gene-editing treatment designed to permanently lower LDL cholesterol with a single infusion.
• Wall Street consensus for LLY is 'Strong Buy' among 31 analysts, with an average price target implying roughly 13% upside from current levels.

Eli Lilly shares are on track for their best month of 2026, up 14% as May draws to a close, lifted by a pair of drug developments that underscore the company's expanding ambitions beyond obesity and into cardiovascular disease.

Lilly's Cholesterol Breakthrough

Late Monday, Lilly released interim Phase 1b trial data for Verve-102, an experimental medicine that uses gene editing to permanently lower LDL ("bad" cholesterol), potentially from a single infusion.

Rather than a daily pill or a recurring injection, Verve-102 is designed to make a one-time edit to the PCSK9 gene in liver cells. PCSK9 is a protein that interferes with the liver's ability to clear LDL from the bloodstream; by blocking it, the treatment aims to reduce cholesterol levels durably with a single dose.

In an interim analysis of 35 participants, the results were notable. PCSK9 protein levels fell by 51% to 88% across dose levels, and LDL cholesterol dropped by up to 62% at the highest dose, with reductions lasting up to 18 months after a single treatment. The trial focused on two high-risk patient groups: people with heterozygous familial hypercholesterolemia, an inherited condition causing dangerously elevated cholesterol from birth, and those with premature coronary artery disease.

Lilly Rides Obesity Drug Wave With Mounjaro

Lilly is also riding the fastest-growing pharmaceutical category in history. From a near-standing start in 2021, the four leading GLP-1 weight-loss drugs — Mounjaro, Ozempic, Zepbound, and Wegovy — are on pace to generate more than $100 billion in sales this year. Lilly's Mounjaro has emerged as the standout, surpassing Merck's cancer blockbuster Keytruda to become the world's best-selling drug last quarter.

Last week, LLY received a fresh wave of analyst upgrades following trial readouts for retatrutide, Lilly's experimental next-generation obesity drug, which helped patients lose more than 28% of their body weight over 18 months. 

According to summaries on The Fly, RBC Capital called the results "a clean win," citing a strong safety profile and best-in-class efficacy across all doses. The firm is modeling a retatrutide launch in 2027, with 2030 sales of $4.9 billion and 2034 sales of $11.0 billion, assigning a 70% probability of success. Truist said the data set a new benchmark for anti-obesity medications and would support approval for patients not adequately served by existing treatments.

Eli Lilly Valuation And Technical Levels

Lilly is just 6.5% below its all-time high in November 2025, the same level at which it briefly became the first healthcare company in history to reach a $1 trillion market capitalization. The stock has maintained its momentum since forming a golden cross in early November, when the 50-day moving average crossed above the 200-day moving average.

Still, the valuation warrants attention. LLY trades at a forward price-to-earnings ratio of 28x, above the S&P 500's 21x and well above Novo Nordisk's 14x. Its RSI of 68.3 sits in borderline overbought territory.

According to Koyfin, Wall Street remains firmly bullish on LLY overall, with a 'Strong Buy' consensus among 31 analysts and an average price target of roughly $1,211, implying about 13% upside from current levels.

What Retail Thinks About LLY Stock

On Stocktwits, sentiment for LLY has shifted from 'bearish' a year ago to 'neutral' at the last close, suggesting caution persists among retail traders despite the strong fundamentals. Engagement for the stock remains robust: followers have jumped 25%, and message volume has surged 250% over the past year.

"LP(a) is the next frontier in cardiovascular care. All hereditary and there is nothing to treat it at the moment. This will be huge," said one bullish user following the latest cholesterol trial.

Another expects LLY to "double within next 3 years!"

Interestingly, the stock is still down about 0.5% year-to-date following nine consecutive years of strong gains, as AI-driven narratives have captured the bulk of investor attention and capital in 2026. However, Goldman Sachs counts LLY among its top picks specifically for its low sensitivity to AI trade rotation and U.S. economic uncertainty.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: BB, SIDU, RGTI Stocks Lead Last Week’s Wildest Upswings: Here's What Happened